ArticleBMC neurology2026
Exploratory proteomic analysis of Megaconial congenital muscular dystrophy skeletal myoblasts suggests cytoskeletal and contractile alterations.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMegaconial congenital muscular dystrophy (CMD) is an ultrarare autosomal recessive disorder characterized by phosphatidylcholine (PC) deficiency due to mutations in the choline kinase B (CHKB) gene. Although the genetic basis and morphological hallmarks of Megaconial CMD have been well characterized, the mechanisms by which lipid imbalance leads to global protein-level remodelling and muscle dysfunction remain poorly understood.
methodsTo address this gap, we performed label-free quantitative LC‒MS/MS proteomic profiling of primary skeletal myoblasts derived from a Megaconial CMD patient and healthy controls. The raw data were processed with Proteome Discoverer 2.2, and the candidate differentially abundant proteins (DAPs) were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses.
resultsData quality assessment confirmed reliable clustering and clear separation between patient and control samples. A total of 218 candidate DAPs were identified, with the majority showing reduced abundance in patient-derived cells. GO and KEGG pathway enrichment analyses suggested enrichment of proteins associated with cytoskeletal organization, muscle contraction, actin-myosin filament sliding, and supramolecular fiber assembly. These findings suggest a potential association with early alterations in structural integrity and contractile machinery in myoblasts and indicate that PC deficiency may affect membrane organization and membrane-cytoskeleton interactions. Additional enriched pathways included protein homeostasis, endoplasmic reticulum processing, and stress response pathways, reflecting broad cellular perturbations. Notably, several cardiomyopathy-related pathways were also represented, likely reflecting shared sarcomeric and cytoskeletal components between skeletal and cardiac muscle.
conclusionTo our knowledge, this study provides the first exploratory proteome-level characterization of Megaconial CMD skeletal myoblasts and identifies candidate protein alterations associated with muscle structural organization, cytoskeletal networks, and intracellular homeostasis, warranting further validation in independent biological samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.